242 related articles for article (PubMed ID: 26989114)
21. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
22. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Pieroni M; Chimenti C; Ricci R; Sale P; Russo MA; Frustaci A
Circulation; 2003 Apr; 107(15):1978-84. PubMed ID: 12668521
[TBL] [Abstract][Full Text] [Related]
23. Apical hypertrophic cardiomyopathy: elegant use of contrast-enhanced echocardiography in the diagnostic work-up.
Walpot J; Pasteuning WH; Shivalkar B
Acta Cardiol; 2012 Aug; 67(4):495-7. PubMed ID: 22998010
[TBL] [Abstract][Full Text] [Related]
24. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
25. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy.
Boyd AC; Lo Q; Devine K; Tchan MC; Sillence DO; Sadick N; Richards DA; Thomas L
J Am Soc Echocardiogr; 2013 Dec; 26(12):1415-23. PubMed ID: 24094560
[TBL] [Abstract][Full Text] [Related]
26. Clinical findings of gadolinium-enhanced cardiac magnetic resonance in Fabry patients.
Nojiri A; Anan I; Morimoto S; Kawai M; Sakuma T; Kobayashi M; Kobayashi H; Ida H; Ohashi T; Eto Y; Shibata T; Yoshimura M; Hongo K
J Cardiol; 2020 Jan; 75(1):27-33. PubMed ID: 31623930
[TBL] [Abstract][Full Text] [Related]
27. An unusual cause of dyspnea.
Jamali AH; Ahmed RM; Stein H
Cardiol Rev; 2004; 12(1):10-4. PubMed ID: 14667257
[TBL] [Abstract][Full Text] [Related]
28. Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease.
Masarone D; Duro G; Dellegrottaglie S; Colomba P; Rubino M; Cirillo A; Pisani A; Caiazza M; Elliott PM; Calabrò P; Pacileo G; Limongelli G
Future Cardiol; 2017 Nov; 13(6):521-527. PubMed ID: 28936893
[TBL] [Abstract][Full Text] [Related]
29. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
30. [Circumscribed apical left ventricular hypertrophy as the cause of a pronounced T-wave negativity].
Maas A; Stellwaag M; Lambertz H
Dtsch Med Wochenschr; 1996 Sep; 121(38):1152, 1153-6, 1157. PubMed ID: 8925735
[TBL] [Abstract][Full Text] [Related]
31. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
32. Utility of tissue characterization in apical hypertrophic cardiomyopathy diagnosis.
Abecasis J; Dourado R; Arroja I; Azevedo J; Silva A
Eur J Echocardiogr; 2009 Mar; 10(2):325-8. PubMed ID: 18755699
[TBL] [Abstract][Full Text] [Related]
33. Late-onset primary LVH HCM versus cardiac fabry variant.
Frustaci A; Pieroni M; Chimenti C
J Am Coll Cardiol; 2002 Apr; 39(8):1405-6; author reply 1406. PubMed ID: 11955864
[No Abstract] [Full Text] [Related]
34. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients.
Senechal M; Germain DP
Clin Genet; 2003 Jan; 63(1):46-52. PubMed ID: 12519371
[TBL] [Abstract][Full Text] [Related]
35. [Cardiac manifestations in Fabry disease].
Lappegård KT; Aass H
Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2395-6. PubMed ID: 11475223
[TBL] [Abstract][Full Text] [Related]
36. Apical hypertrophy associated with rapid T wave inversion on the electrocardiogram.
Yamanari H; Saito D; Mikio K; Nakamura K; Nanba T; Morita H; Mizuo K; Sato T; Ohe T
Heart Vessels; 1995; 10(4):221-4. PubMed ID: 8530329
[TBL] [Abstract][Full Text] [Related]
37. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy.
Hoigné P; Attenhofer Jost CH; Duru F; Oechslin EN; Seifert B; Widmer U; Frischknecht B; Jenni R
Int J Cardiol; 2006 Aug; 111(3):413-22. PubMed ID: 16307805
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
39. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance.
Maron MS; Maron BJ; Harrigan C; Buros J; Gibson CM; Olivotto I; Biller L; Lesser JR; Udelson JE; Manning WJ; Appelbaum E
J Am Coll Cardiol; 2009 Jul; 54(3):220-8. PubMed ID: 19589434
[TBL] [Abstract][Full Text] [Related]
40. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy.
Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L
Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
